Pursuant to Regulation 34(1)(a) and Regulation 30 read with Event 12 of Part- A Para A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Colinz Laboratories Ltd has submitted its 39th Annual Report for FY 2024-25 along with the Notice convening the 39th AGM, to be held on Tuesday, 30th September 2025 at 2:30 PM (IST) via video conferencing. Total revenue for FY25 stood at Rs. 682.56 Lacs, down from Rs. 730.46 Lacs in FY24, while net profit rose modestly to Rs. 49.66 Lacs (vs Rs. 48.67 Lacs earlier), with total profit after tax and OCI at Rs. 52.55 Lacs. The Board has not recommended any dividend for the year, with paid-up equity capital at Rs. 251.91 Lacs. Key AGM resolutions include the re-appointment of Dr. Mani L. S. (retiring by rotation), appointment of Mr. Swapnil Jayeshbhai Madiyar as Non-Executive Non-Independent Director, and re-appointment of Mr. N. K. Menon as Whole-Time Director & CEO for one year (Oct 2025–Sept 2026) with a proposed salary of Rs. 7.5 to 12.5 Lacs per annum plus allowances.
The slight revenue dip is mildly negative, but stable net profit and a retained surplus of Rs. 405.63 Lacs indicate sound financial health. Shareholders get no dividend this year as the company plans to plough back earnings. The re-appointments ensure leadership continuity with no major operational disruption expected.